|
Jun 28, 2011, 02.29 PM IST
Jubilant Life Sciences has intraday target of Rs 183.50, says Ashish Tater, Fort Share Broking
Tater told CNBC-TV18, "Jubilant Life Sciences is undervalued by atleast 20% at current levels and we have a medium-term target of close to Rs 210 mark. Looking its business into Osteoporosis and others, this particular stock is definitely to get rerating and I have an intermediate target of close to Rs 210 mark and intraday target of close to Rs 183.50. Click HERE to know the rules and follow the score card
Set email alert for |
 From DJ EU Officials Spain Aid Cap Of 100 Bn Euros 'should Be Enough'  The latest earning numbers FIRST on CNBC-TV18
News Videos
|
